ARTICLE | Top Story
Merck dropping taranabant for obesity
October 3, 2008 12:28 AM UTC
Merck (NYSE:MRK) said it ended development of taranabant (formerly MK-0364) to treat obesity after pooled data from a Phase III program showed "efficacy and adverse events were dose related, with grea...